| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 0.77 Billion |
| Market Size (2030) | USD 1.09 Billion |
| CAGR (2025 - 2030) | 7.10 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Cervical Dysplasia Market Analysis
The Cervical Dysplasia Market size is estimated at USD 0.77 billion in 2025, and is expected to reach USD 1.09 billion by 2030, at a CAGR of 7.1% during the forecast period (2025-2030).
Human Papillomavirus (HPV) is a primary cause of cervical cancer. The rising incidence of cervical cancer, driven by persistent infections such as HPV and other sexually transmitted diseases (STDs), is spurring the growth of the cervical dysplasia market. For example, data from the HPV Information Centre published in March 2023 indicates that approximately 2.972 million women aged 15 and older were at risk of developing cervical cancer in 2023. Furthermore, the same source reported that 604,127 women were diagnosed with cervical cancer annually, making it the 4th most common cancer among women globally. Consequently, as cervical cancer prevalence rises, so does the demand for diagnostic solutions. Early detection and prompt treatment are vital in stunting cancer cell growth, thus propelling market expansion.
In addition, global government bodies and market players are ramping up awareness campaigns, screenings, and treatment availability for cervical dysplasia. For instance, in March 2024, Becton, Dickinson and Company launched an awareness initiative in India, spotlighting cervical cancer screening. The initiative underscored the benefits of early detection via liquid-based cytology and HPV DNA testing. As a result, with the uptick in awareness initiatives, the market for cervical dysplasia is poised for growth during the forecast period.
Furthermore, an increasing number of product approvals for more effective cervical dysplasia screening tests are set to propel market growth. For instance, in May 2024, Roche Diagnostics secured FDA approval for its HPV self-collection solutions in the U.S., broadening access and screening avenues to aid in cervical cancer elimination. Such endorsements are anticipated to bolster the demand for cervical dysplasia screening tests, facilitating early disease detection. Additionally, healthcare providers now have tools that can pinpoint pre-cancerous changes with greater accuracy, further driving market growth.
Given the rising cervical cancer prevalence, bolstered government initiatives for its prevention, and an uptick in product approvals, the market is projected to expand during the forecast period.
However, challenges remain. Limited awareness in developing nations and the high cost of treatments could temper the market's growth trajectory during the forecast period.
Cervical Dysplasia Market Trends
Human Papillomavirus (HPV) Test Segment is Expected to Witness Significant Growth Over the Forecast Period
The HPV test serves as a crucial medical diagnostic tool, identifying high-risk types of human papillomavirus linked to cervical dysplasia and cervical cancer.
Due to its effectiveness, flexibility, and cost-efficiency, the HPV test segment is poised to capture a significant market share during the forecast period. Favorable reimbursement policies in developed nations further bolster its adoption. The affordability of these tests has led to their widespread use in low- and middle-income countries. For instance, data published in December 2023 in the Nature Medicine Journal highlighted that primary human papillomavirus (HPV) screening, when conducted every five years, can reduce age-standardized cervical cancer mortality rates by 63–67%. Such compelling benefits underscore the HPV test's role in propelling the cervical dysplasia market, offering a precise and efficient means for early detection of pre-cancerous changes.
Technological advancements in HPV testing are set to further accelerate segment growth. A case in point: in June 2022, F. Hoffmann-La Roche Ltd rolled out a human papillomavirus (HPV) self-sampling solution in countries recognizing the CE mark. This innovative solution empowers patients to privately collect samples at healthcare facilities. With its endorsement as a primary test, global reach, and the rising trend of self-sampling, the HPV testing market is on a trajectory for robust growth.
Additionally, heightened government initiatives promoting HPV testing for cervical cancer screenings are anticipated to fuel market expansion. For example, in March 2023, the International Agency for Research on Cancer (IARC) unveiled the IARC Atlas, a groundbreaking online platform aimed at aiding health professionals in leveraging HPV tests for cervical screenings and managing HPV-positive women. This tool offers vital guidelines and evidence-based practices, equipping healthcare providers to enhance screening precision and patient care. By streamlining the implementation of HPV testing, the IARC Atlas is set to bolster awareness and adoption of cervical cancer preventive measures. As more professionals embrace these guidelines, the demand for HPV testing is expected to surge, propelling segment growth.
In summary, with technological strides in HPV testing and a surge in government-backed initiatives, the adoption of HPV tests is on the rise, signaling a bullish outlook for the market.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Dominate the Cervical Dysplasia Market
North America leads the cervical dysplasia market, driven by technological advancements in screening tests, rising prevalence of related diseases like cervical cancer and STIs, heightened awareness from screening programs, and supportive government initiatives. These factors are poised to boost the adoption of diagnostic tests and therapies for cervical dysplasia in the region.
In the U.S., increasing FDA approvals for HPV tests allowing self-collection in healthcare settings are set to propel regional market growth. For example, in May 2024, the FDA expanded approvals for two tests detecting cancer-causing strains of human papillomavirus (HPV) in the cervix. The approved tests include Onclarity HPV from Becton, Dickinson and Company (BD) and cobas HPV from Roche Molecular Systems. The introduction of a self-collection option in healthcare settings is anticipated to improve access to screening tests, thereby influencing demand in the cervical dysplasia market.
Furthermore, U.S. government initiatives aimed at bolstering human papillomavirus (HPV) testing are projected to stimulate the cervical dysplasia market's growth. For instance, in January 2024, the National Cancer Institute (NCI) unveiled a clinical trial network focused on the "self-collection" method for HPV testing, a proactive measure against cervical cancer. If proven effective, this method could greatly boost cervical cancer screening rates. The initiative supports the Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial Network, which will independently assess the clinical performance of various HPV testing methods using different self-collection devices and assay combinations currently under FDA review.
Moreover, ongoing R&D underscoring the significance of HPV-based screening tests in mitigating cervical cancer risk is anticipated to bolster regional market growth. For instance, a June 2024 modeling study in the CMAJ (Canadian Medical Association Journal) indicated that adopting HPV-based screening in British Columbia could eradicate cervical cancer in the province by 2040. The research emphasized that while the Pap test has been the primary screening tool for years, HPV-based screening offers superior accuracy in detecting cervical precancer. Additionally, since HPV-based screening can be conducted on patient-collected samples rather than solely by healthcare providers, it enhances access and uptake. Such insights underscore the value of HPV-based screening tests, fueling market expansion.
In conclusion, bolstered by government initiatives and product approvals, the demand for diagnostic tests in North America is set to surge, propelling the market's growth in the coming years.
Get Analysis on Important Geographic Markets
Download PDF
Cervical Dysplasia Industry Overview
The cervical dysplasia market is highly competitive with many key players dominating the market. The presence of major market players, such as Abbott Laboratories, Asieris Pharmaceuticals, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Hologic Inc., and others are intensifying the competition. The market players are adopting strategies, such as innovations and technological advancements in diagnostic test kits as well as devices to sustain the increasing market rivalry.
Cervical Dysplasia Market Leaders
-
Qiagen
-
Abbott Laboratories
-
F. Hoffmann-La Roche Ltd.
-
Becton, Dickinson and Company
-
Hologic, Inc.
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Cervical Dysplasia Market News
- May 2024: Becton, Dickinson, and Company has teamed up with Healthians, a leading diagnostics service based in Gurugram, to enhance cervical cancer screening. This collaboration introduces a groundbreaking option: women in India can privately self-collect samples from the comfort of their homes.
- February 2024: Hologic, Inc. has secured clearance from the U.S. Food and Drug Administration (FDA) for its innovative Genius Digital Diagnostics System, which incorporates the Genius Cervical AI algorithm. This milestone positions Hologic as the pioneer, boasting the first and only FDA-cleared digital cytology system. This system uniquely melds deep-learning-based artificial intelligence (AI) with cutting-edge volumetric imaging technology, enhancing the identification of pre-cancerous lesions and cervical cancer cells.
Cervical Dysplasia Industry Segmentation
As per the scope of the report, cervical dysplasia refers to abnormal cell changes on the cervix, which can be precursors to cervical cancer if not monitored or treated. The cervical dysplasia market is segmented by diagnosis type, end-user, and geography. By diagnosis type, the market is segmented into diagnostic tests and diagnostic devices. The diagnostic tests segment is further classified into HPV test, Pap smear test, and biopsy test. By end-user, the market is segmented into hospitals, specialty clinics, cancer and radiation therapy centers, and diagnostic centers. The report also covers the market size and forecasts for the cervical dysplasia market in 17 countries across major regions. For each segment, the market sizing and forecasts have been done on the basis of value (USD).
| By Diagnosis Type | Diagnostic Test | HPV Test | |
| Pap Smear Test | |||
| Biopsy Test | |||
| Diagnostic Device | |||
| By End User | Hospitals | ||
| Specialty Clinics | |||
| Cancer and Radiation Therapy Centers | |||
| Diagnostic Centers | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Need A Different Region or Segment?
Customize Now
Cervical Dysplasia Market Research FAQs
How big is the Cervical Dysplasia Market?
The Cervical Dysplasia Market size is expected to reach USD 0.77 billion in 2025 and grow at a CAGR of 7.10% to reach USD 1.09 billion by 2030.
What is the current Cervical Dysplasia Market size?
In 2025, the Cervical Dysplasia Market size is expected to reach USD 0.77 billion.
Who are the key players in Cervical Dysplasia Market?
Qiagen, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company and Hologic, Inc. are the major companies operating in the Cervical Dysplasia Market.
Which is the fastest growing region in Cervical Dysplasia Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Cervical Dysplasia Market?
In 2025, the North America accounts for the largest market share in Cervical Dysplasia Market.
What years does this Cervical Dysplasia Market cover, and what was the market size in 2024?
In 2024, the Cervical Dysplasia Market size was estimated at USD 0.72 billion. The report covers the Cervical Dysplasia Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Cervical Dysplasia Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Cervical Dysplasia Industry Report
Statistics for the 2025 Cervical Dysplasia market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Cervical Dysplasia analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
